ASCO 2025: Q&A with Aixial’s clinical research experts
Ashley Hunter /
Exec. Director Strategic Development and Delivery
What sets Aixial Group apart from other CRO companies ?
Ashley — Our success is built on a people-first approach, distinguishing us from other CROs. We prioritize building personalized client relationships through open, transparent, and consistent communication with sponsors, sites, and key stakeholders. By fostering clear dialogue, we gain a deep understanding of our sponsors’ objectives, enabling us to tailor processes and workflows that align seamlessly with their goals. Each clinical trial managed by Aixial is supported by a dedicated team of experts, equipped with specialized training and therapeutic experience to meet the study’s unique requirements. While our expertise spans more than 26 therapeutic areas, we maintain a strategic focus on oncology, CNS, rare disease, and advanced medicines such as cell and gene therapies, as well as radiotherapeutics, ensuring depth of knowledge without dilution across numerous indications.
Additionally, every project benefits from direct engagement by Senior Management, ensuring hands-on oversight, accessibility for sponsors, and agile decision making when challenges arise. This leadership involvement enhances operational efficiency and responsiveness, positioning us as a trusted, proactive partner in clinical research.
Why attendees should visit us at ASCO 2025?
Valentina — Aixial is a global full service CRO with proven record of successful delivery of clinical trials in various areas of oncology. Our team is known for strong expertise in the oncology and personalized approach and is ready to give advice regarding the clinical research program from pre-clinical development to post marketing management.
Ashley — Come discover how our people-first approach, commitment to performance and quality, and 20+ years of global clinical trial expertise can drive the success of your study. Whether you’re navigating pre-clinical testing, securing funding, preparing for a pivotal trial, or anywhere in between, we’re here to help you move forward. We invite you to visit us at booth #27150 to connect and explore how our expertise can support your journey and accelerate your next milestone. Let’s collaborate to create a solution tailored to your unique trial needs!
Valentina Zhukova-Harrill /
Chief Medical Officer
How do you imagine the future of the clinical research sector or the life sciences industry?
Ashley — Clinical research continues to evolve, with personalized medicine and targeted therapies driving significant advancements. These patient-centric approaches are transforming treatment by tailoring interventions based on genetic, molecular, biological, and lifestyle factors, moving beyond the traditional one-size-fits-all model. The expected benefits include greater drug efficacy, improved safety profiles, and higher survival rates for conditions that were once considered fatal. Moreover, targeted therapies minimize unnecessary drug exposure, reducing potential side effects and enhancing overall patient outcomes.
Another area experiencing rapid growth is the integration of technology in clinical research and healthcare. From wearable devices enabling real-time health monitoring to the expansion of telemedicine, digital innovations are improving patient accessibility and data collection. Artificial intelligence (AI) is reshaping clinical trials, supporting predictive analytics, drug interaction simulations, and adaptive trial designs to enhance efficiency and accelerate time to regulatory approval. As these advancements continue, we can expect safer, more streamlined trials that prioritize both scientific progress and patient well-being.
Valentina — The clinical research, as a part of the life sciences industry, is continuing to grow, and this trend is not poised to decline due to demand for new ground-breaking therapies. It is expected to be significantly modelled by technological advancements and evolving regulatory landscapes in the coming years, with a focus on personalized medicine, data-driven insights, and patient-centric approaches.
Through your work, how do you feel you are contributing to building a better world?
Valentina — Dr. Robert Zon, the 61st President of the American Society of Clinical Oncology (ASCO) for 2024-2025 announce her presidential theme 2025 as Driving Knowledge to Action: Building a Better Future. This theme reflects Aixial philosophy to offer our sponsors the partnership, smart and effective strategic planning in order to optimize the drug development process and make their clinical trials successful using our highly knowledgeable and experience team. This approach is a way to build a better future and I am proud to be a part of the team that is building future.
